Yep indeed. Wow.
Until we get more data on the MAST and OASIS trials (Vaxinia and OnCARlytics), it all comes down to a matter of hints and conjecture based on interviews like these - balanced on the other side against the natural tendency to view a depressed share price as evidence that the company is somehow failing.
However, given the absence of any data pointing to an actual failure, the depressed share price is
really only evidence of the obvious: that the share market thinks short term and is fear driven, and that most investors simply lack the time to read up on and to understand the science.
Myself - I am fortunate that I do have the time and interest to read up on the science. I'm not immune to fear - but I'm disinclined to take that emotion seriously unless it has a basis in fact.
SO looking at those facts, what we know so far (with regard to Vaxinia and OnCARlytics) is that both treatments have exceptional pre-clinical results.
We also know that Vaxinia has exceptional safety and tolerability, and that OnCARlytics seems to have this also - as you would expect, given that it is the same virus with one minor genetic modification.
On the really big issue - clinical effectiveness in humans - Vaxinia has very encouraging results released in November, and those results were based on dosage at mostly low levels, with a few patients just starting their mid level dosage.
We await the next cut of 3rd party reviewed data, but we do know that dosage has increased by two orders of magnitude since November - and still with no doe limiting safety/tolerability problems. We also know that Leslie Chong and Yuman have access to the raw trial data that we do not yet have access to.
So those are the scientific facts to date.
And now we have two new interviews with Leslie Chong and Yuman Fong.
I'm not going to analyse them frame by frame, and I make no claim to be a master of body language - so take what I say here as "my opinion only." However - both interviews show the CEO and the inventor of CF33 simply brimming with confidence.
To me, the most breathtaking moment was in the JustStocks interview at 08:30 when Yuman said: "
We are attempting to find a universal therapy for any kind of solid tumour."
That is a simply incredible statement for a high profile cancer researcher to make. Even hinting that a universal treatment for cancer might some day be possible is to risk ridicule.
When Yuman said similar things, two years ago, ahead of the clinical trial, it seemed very very brave and optimistic to me.
For Yuman to say it now - when they have extensive clinical trial data available for him to see - well that just seems like a
HUGE expression of confidence based on a whole lot more information which he is has access to.
He goes on to say: "
So that's a big big step. When we first started saying we were gonna go do that, I ... I... we had only animal data. Now we have human data."
Sure - of course - ahead of proper verified and reviewed analysis he does have to make clear that success is not a matter of established fact: "
So, ah, I'm hoping it pans out. You know, dreaming big but ah, now we are starting to get data, so very excited about it."
Everyone needs to draw their own conclusions.
My conclusion:
Success is never certain, but the chances of success are far far higher than the Imugene share price might lead you to believe.
The magnitude of that success - if it does indeed occur - could be truly shocking.
I've been in for years.
And I'm staying in.
Cheers
Dave
PS Friend
@Fact Finder - just read your comment. 1000% agree!!!!!
(20min delay)